+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Attenuation of insulin resistance by chronic beta2-adrenergic agonist treatment possible muscle specific contributions

Attenuation of insulin resistance by chronic beta2-adrenergic agonist treatment possible muscle specific contributions

Life Sciences 69(5): 599-611

A possible mechanism by which chronic clenbuterol treatment causes multiple physiological changes in skeletal muscle that leads to reduced insulin resistance in the obese Zucker rat (fa/fa) was investigated. Animals were gavaged with clenbuterol (CB) (0.8 mgcntdotkg-1cntdotday-1), terbutaline (TB) (1.0 mgcntdotkg-1cntdotday-1), or control (CT) vehicle for six weeks. Oral glucose tolerance and insulin responses were markedly improved in CB rats and impaired in TB rats. CB treatment caused a 24-34% gain in muscle mass in all muscle fiber types, and increases in 3-O-methyglucose transport (2-fold) and GLUT4 concentration (57%) in fast twitch glycolytic (FG) muscle. Oxidative capacity was reduced in both FG (47%) and fast twitch oxidative (FO) muscle (30%), but not in slow twitch oxidative (SO) muscle. Null model analysis for receptor occlusion demonstrated that most functional beta-adrenoceptors were lost in FO (82%) and FG (89%) fibers, but not in SO fibers. We propose that hypertrophy is the result of continuous direct activation of beta-adrenoceptors while loss in oxidative capacity may be the result of receptor down regulation. Improvements in insulin resistance may have been due, in part, to both increases in lean body mass and specific adaptations in FG muscle.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 010217636

Download citation: RISBibTeXText

PMID: 11510954

Related references

Attenuation of insulin resistance by chronic b-adrenergic agonist treatment: possible muscle specific contributions. Life Sciences 69(5): 9-611, 2001

The stability of the agonist beta2-adrenergic receptor-Gs complex: evidence for agonist-specific states. Molecular Pharmacology 52(1): 144-154, 1997

Inhibition of agonist-specific desensitization of beta2 adrenergic receptors. Official Gazette of the United States Patent & Trademark Office Patents 1237(1), Aug 1, 2000

Mitochondrial dysfunction in insulin resistance: differential contributions of chronic insulin and saturated fatty acid exposure in muscle cells. Bioscience Reports 32(5): 465-478, 2013

Anabolic effects of a non-myotoxic dose of the beta2-adrenergic receptor agonist clenbuterol on rat plantaris muscle. Muscle & Nerve 35(2): 217-223, 2006

Persistent agonist-mediated regulation of human beta1- and beta2-adrenergic receptors is subtype-specific. FASEB Journal 15(4): A217, March 7, 2001

Agonist regulation of human beta2-adrenergic receptor mRNA stability occurs via a specific AU-rich element. Journal of Biological Chemistry 273(6): 3223-3229, 1998

Beta2-Adrenergic receptor ARG16 to GLY polymorphism and detrimental effects of regular inhaled beta2-agonist therapy. European Respiratory Journal 12(SUPPL 28): 324S, Sept, 1998

Arg16 homozygosity of the beta2-adrenergic receptor improves the outcome after beta2-agonist tocolysis for preterm labor. Clinical Pharmacology and Therapeutics 78(6): 656-663, 2005

Characterization of chimeric beta1/beta2-adrenergic receptors to elucidate the structural requirements of the beta2-selectivity of a carbostyril beta-agonist. FASEB Journal 12(8): A1456, April 24, 1998

Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 163(5): 1087-1092, 2001

Beta2-adrenergic agonist-induced hypertrophy of the quadriceps skeletal muscle does not modulate disease severity in the rodent meniscectomy model of osteoarthritis. Osteoarthritis and Cartilage 18(4): 555-562, 2010

Clenbuterol, a beta2-adrenergic agonist, reciprocally alters PGC-1 alpha and RIP14 and reduces fatty acid and pyruvate oxidation in rat skeletal muscle. 2012

Analysis of full and partial agonists binding to beta2-adrenergic receptor suggests a role of transmembrane helix V in agonist-specific conformational changes. Journal of Molecular Recognition 22(4): 307-318, 2009

The beta2-adrenergic modulator celiprolol reduces insulin resistance in obese Zucker rats. Life Sciences 64(22): 2071-2079, 1999